1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OMB110911, EudraCT 2008-004932-19, NCT00748189
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0419, 7303, NCI-7303, NCT00262743, CLLT-MAYO-MC0419
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-1026, NCT00472849
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 0 to 55
Sponsor: Other
Protocol IDs: 8717, NCT00673114
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: MOZ00207, NCT00694590
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCSD-080422, NCT00949988
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: JHOC-J0260, J0260, JHOC-03022409, NCT00278161
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: LYMNHL0020, 4328-07, 95140, LYMNHL0020, NCT00185731, NCT00185731
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAM203, NCT00328198
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MAYO-MC0785, MC0785, GENENTECH-MC0785, BAYER-MC0785, NCT00562328
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-14978, RV-CLL-PI-067, IRB 105338, NCT00609869
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRC014, Celgene # RV-CLL-PI-0223, NCT00628238
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 11300A, NCT00683046
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: 08-LEUK-07-MCC/CI, NCT00758693
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 2008-0431, NCT00759798
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPKC412D2201, NCT00782067
|
|
17.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MCCRC-RC0783, RC0783, MCCRC-08-002080, NCT00816595
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 70
Sponsor: NCI, NHLBI
Protocol IDs: 606, U01 HL069294, NCT00864227
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MU9230, NCT00899353
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 09-0679-04, NCT00997386
|
|
21.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 19 to 75
Sponsor: Other
Protocol IDs: 083-09, NCI-2009-01552, NCT01044745
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 26
Sponsor: Other
Protocol IDs: CHNY 525, AAAB2879, NCT01049854
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 17656, CLONTAK, NCT00224354
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 0C-07-6, NCT00630760
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP24534-07-101, NCT00660920
|
